Edwards Lifesciences has entered into a definitive agreement to acquire certain assets of the CardioVations division of Ethicon.
The purchase price was approximately $27 million and includes inventory, related intellectual property rights and the assumption of certain liabilities.
The Irvine, Calif.-based Edwards said that the CardioVations' product line includes the Port-Access products, such as the EndoCPB and EndoDirect systems for minimally invasive heart valve surgery for performing port-access cardiac valve procedures.
Edwards anticipates that the acquisition will close by the end of 2007. The acquisition is subject to customary closing conditions.